Engert A - Search Results

1

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.

Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, Schmitz N, Engert A, Schaefer-Eckart K, Birkmann J. Wilhelm M, et al. Among authors: engert a. Blood Cancer J. 2016 Jul 29;6(7):e452. doi: 10.1038/bcj.2016.63. Blood Cancer J. 2016. PMID: 27471868 Free PMC article.

2

Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.

Hiddemann W, Unterhalt M, Pott C, Wörmann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert J, et al. Hiddemann W, et al. Among authors: engert a. Semin Oncol. 1993 Oct;20(5 Suppl 7):28-31. Semin Oncol. 1993. PMID: 8235693 Clinical Trial.

3

A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.

Engert A, Schnell R, Küpper F, Reiser M, Engelhard M, Wilhelm M, Lathan B, Baltes-Engler S, Winterhalter B, Scheulen ME, Dederichs B, Tesch H, Wörmann B, Diehl V. Engert A, et al. Leuk Lymphoma. 1997 Feb;24(5-6):513-22. doi: 10.3109/10428199709055588. Leuk Lymphoma. 1997. PMID: 9086441 Clinical Trial.

4

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

Josting A, Kàtay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD. Josting A, et al. Among authors: engert a. Ann Oncol. 1998 Mar;9(3):289-95. doi: 10.1023/a:1008283909959. Ann Oncol. 1998. PMID: 9602263 Clinical Trial.

5

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Coiffier B, et al. Among authors: engert a. Blood. 1998 Sep 15;92(6):1927-32. Blood. 1998. PMID: 9731049 Free article. Clinical Trial.

6

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Rüffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dölken G, Worst P, Koch P, Schmitz N, Bruntsch U, Tirier C, Müller U, Loeffler M. Tesch H, et al. Among authors: engert a. Blood. 1998 Dec 15;92(12):4560-7. Blood. 1998. PMID: 9845521 Free article. Clinical Trial.

7

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wörmann B, Münch R, Diehl V, Engert A. Reiser M, et al. Among authors: engert a. Leuk Lymphoma. 1998 Oct;31(3-4):359-66. doi: 10.3109/10428199809059229. Leuk Lymphoma. 1998. PMID: 9869200 Clinical Trial.

8

Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.

Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl V, Söhngen D, Engert A. Reiser M, et al. Among authors: engert a. Bone Marrow Transplant. 1999 Jun;23(12):1223-8. doi: 10.1038/sj.bmt.1701791. Bone Marrow Transplant. 1999. PMID: 10414907 Clinical Trial.

9

Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.

Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A. Josting A, et al. Among authors: engert a. Leuk Lymphoma. 2000 Mar;37(1-2):115-23. doi: 10.3109/10428190009057634. Leuk Lymphoma. 2000. PMID: 10721775 Clinical Trial.

10

Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.

Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A. Josting A, et al. Among authors: engert a. Leuk Lymphoma. 2000 Mar;37(1-2):185-7. doi: 10.3109/10428190009057644. Leuk Lymphoma. 2000. PMID: 10721785 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

597 results

Search Page

Filters